Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice

Antimicrobial Agents and Chemotherapy
M KendeP G Canonico


The therapeutic efficacy of polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine and carboxymethyl cellulose [poly(ICLC)] given alone or in combination with ribavirin was evaluated in Swiss Webster mice infected with Rift Valley fever virus. Four or more 20-micrograms doses of poly(ICLC) given at various intervals beginning 24 h after infection protected all mice against death. On the other hand, a treatment regimen consisting of only three doses of poly(ICLC) given 24 h postinfection resulted in a 50% survival rate. When initiated 48 h postinfection, an extended treatment regimen with the same dose was required to yield 40% survivors. Lower doses (5 micrograms) of poly(ICLC) per mouse were only marginally effective even when six injections were given between days 1 and 9 postinfection. The combined administration of ribavirin and poly(ICLC) initiated as late as 48 h postinfection was effective even when treatment consisted of doses that were ineffective when either drug was used alone.


Jan 1, 1979·Transactions of the Royal Society of Tropical Medicine and Hygiene·J M Meegan
Mar 1, 1983·European Journal of Pediatrics·S Levin
Aug 1, 1984·The Journal of Antimicrobial Chemotherapy·P G CanonicoJ W Huggins
Jan 1, 1980·Annual Review of Pharmacology and Toxicology·R A SmithR K Robins


Sep 1, 1993·Antiviral Research·G Andrei, E De Clercq
Jul 20, 1999·International Journal of Immunopharmacology·R L MillerM A Tomai
Aug 29, 2012·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Camila C DiasMarvin J Grubman
Mar 28, 2009·International Journal of Molecular Sciences·Mary E Christopher, Jonathan Wong
Jun 16, 1992·Annals of the New York Academy of Sciences·G H TignorC A Hanham
Jun 16, 1992·Annals of the New York Academy of Sciences·M Kende
Jun 16, 1992·Annals of the New York Academy of Sciences·Robert W SidwellM Kende

Related Concepts

Poly ICLC, sodium salt
Drug Administration Schedule
Interferon Inducers
Poly I-C

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.